Limosilactobacillus reuteri

Discovery

At the turn of the 20th century, L. reuteri was recorded in scientific classifications of lactic acid bacteria, though at this time it was mistakenly grouped as a member of Lactobacillus fermentum. In the 1960s, further work by microbiologist , for whom the species eventually was named, reclassified the species as L. fermentum biotype II.

Significant differences were found between biotype II and other biotypes of L. fermentum, to the point that in 1980 it was identified as a distinct species and the formal species identity, L. reuteri, was proposed. In April 2020, L. reuteri was reassigned to the genus Limosilactobacillus.

Prevalence

Limosilactobacillus reuteri is found in a variety of natural environments. It has been isolated from many foods, especially meats and dairy products. It appears to be essentially ubiquitous in the animal kingdom, having been found in the gastrointestinal tracts and feces of healthy humans, sheep, chickens, pigs, and rodents. It is the only species to constitute a "major component" of the Lactobacillus genus present in the gut of each of the tested host animals, and each host seems to harbor its own specific strain of L. reuteri. It is possible that L. reuteri contributes to the health of its host organism in some manner.

Limosilactobacillus reuteri is present as a dominant member of fermenting organisms in type II sourdoughs; several metabolic traits of L. reuteri, including exopolysaccharide formation and conversion of glutamine to glutamate, improve bread quality.

Effects

Antimicrobial

Limosilactobacillus reuteri is known to produce reuterin,{{cite journal | doi-access = free

Reuterin

In the late 1980s, Walter Dobrogosz, Ivan Casas and colleagues discovered that L. reuteri produced a novel broad-spectrum antibiotic substance via the organism's fermentation of glycerol. They named this substance reuterin, after Reuter. At concentrations above 1.4 M, the HPA dimer was predominant. However, at concentrations relevant for biological systems, HPA hydrate was the most abundant, followed by the aldehyde form.

Reuterin inhibits the growth of some harmful Gram-negative and Gram-positive bacteria, along with yeasts, fungi and protozoa. Researchers found that L. reuteri can secrete sufficient amounts of reuterin to achieve the desired antimicrobial effects. Furthermore, since about four to five times the amount of reuterin is needed to kill "good" gut bacteria (i.e. L. reuteri and other Lactobacillus species) as "bad", this would allow L. reuteri to remove gut invaders without harming other gut microbiota.

Some studies questioned whether reuterin production is essential for L. reuteris health-promoting activity. The discovery that it produces an antibiotic substance led to a great deal of further research. In early 2008, L. reuteri was confirmed to be capable of producing reuterin in the gastrointestinal tract, improving its ability to inhibit the growth of E. coli.

The gene cluster controlling the biosynthesis of reuterin and cobalamin in the L. reuteri genome is a genomic island acquired from an anomalous source.

Clinical results in humans

Although L. reuteri occurs naturally in humans, it is not found in all individuals. Dietary supplementation can sustain high levels of it in those with deficiencies. Oral intake of L. reuteri has been shown to effectively colonize the intestines of healthy individuals. Colonization begins within days of ingestion, although levels drop months later if intake is stopped. L. reuteri is found in breast milk. Oral intake on the mother's part increases the amount of L. reuteri present in her milk, and the likelihood that it will be transferred to the child.

Safety

Manipulation of gut microbiota is a complex process that may cause bacteria-host interactions. Although probiotics in general are considered safe, concerns exist about their use in certain cases. Some people, such as those with compromised immune systems, short bowel syndrome, central venous catheters, heart valve disease, and premature infants, may be at higher risk for adverse events. Rarely, consumption of probiotics may cause bacteremia, fungemia and sepsis, potentially fatal infections, in children with compromised immune systems or who are already critically ill.

Intestinal health

One of the better documented effects of L. reuteri is a significant reduction of symptom duration in pediatric diarrheal disease. L. reuteri is effective as a prophylactic for this illness; children fed it while healthy are less likely to fall ill with diarrhea. With regard to prevention of gut infections, comparative research found L. reuteri to be more potent than other probiotics. Animal research found it to reduce motor complexes and thus intestinal motility.

Limosilactobacillus reuteri may be effective treating necrotizing enterocolitis in preterm infants. Meta-analysis of randomized studies suggests that L. reuteri can reduce the incidence of sepsis and shorten the required duration of hospital treatment in this population.

Limosilactobacillus reuteri is an effective treatment against infant colic. Studies suggest that colicky infants treated with L. reuteri experience a reduction in time spent crying compared to those treated with simethicone or placebo. However, colic is still poorly understood, and it is not clear why or how L. reuteri ameliorates its symptoms. One theory holds that affected infants cry because of gastrointestinal discomfort; if this is the case, it is plausible that L. reuteri somehow acts to lessen this discomfort, since its primary residence is inside the gut.

Gastric health

Limosilactobacillus reuteri have a pronounced anti-helicobacter activity and its use as adjuvant therapy of H. pylori in children appears to be very promising, especially in the case of detection of infection with H. pylori with no absolute indication of eradication.

Growing evidence indicates L. reuteri is capable of fighting the gut pathogen Helicobacter pylori, which causes peptic ulcers and is endemic in parts of the developing world. One study showed dietary supplementation of L. reuteri alone reduces, but does not eradicate, H. pylori in the gut. Another study found the addition of L. reuteri to omeprazole therapy dramatically increased (from 0% to 60%) the cure rate of H. pylori-infected patients compared to the drug alone. Yet another study showed that L. reuteri effectively suppressed H. pylori infection and decreased the occurrence of dyspeptic symptoms, although it did not improve the outcome of antibiotic therapy.

Limosilactobacillus reuteri has the potential to suppress H. Pylori infection and may lead to an improvement of H. Pylori-associated gastrointestinal symptoms, reducing specific symptoms such as diarrhea and frequent abdominal distention. In the future, L. reuteri can become a central part of a strategy to avoid using antibiotics and fighting antibiotic resistance in H. pylori infections and besides fighting antibiotics resistance, L. reuteri may be a great alternative treatment for H. pylori causing fewer side effects than antibiotics.

Oral health

Limosilactobacillus reuteri may be capable of promoting dental health, as it has been proven to kill Streptococcus mutans, a bacterium responsible for tooth decay. A screen of several probiotic bacteria found L. reuteri was the only tested species able to block S. mutans. Before testing in humans began, another study showed L. reuteri had no harmful effects on teeth. Clinical trials proved that people whose mouths are colonized with L. reuteri (via dietary supplementation) have significantly less S. mutans. Since these studies were short-term, it is not known whether L. reuteri prevents tooth decay. However, since it is able to reduce the numbers of an important decay-causing bacterium, this would be expected.

Gingivitis may be ameliorated by consumption of L. reuteri. Patients afflicted with severe gingivitis showed decreased gum bleeding, plaque formation and other gingivitis-associated symptoms compared with placebo after chewing gum containing L. reuteri.

Bone density

Lactobacillus reuteri and other probiotics may influence the gut microbiome in ways that protect against bone loss, common in post-menopausal women.

General health

By protecting against many common infections, L. reuteri promotes overall wellness in both children and adults. Double-blind, randomized studies in child care centers have found L. reuteri-fed infants fall sick less often, require fewer doctor visits and are absent fewer days from the center compared to placebo and to the competing probiotic Bifidobacterium lactis.

Similar results have been found in adults; those consuming L. reuteri daily end up falling ill 50% less often, as measured by their decrease use of sick leave.

Results in animal models

Scientific studies that require harming the subjects (for example, exposing them to a dangerous virus) cannot be conducted in humans. Therefore, many of L. reuteri's benefits have been studied only in different animal species, such as pigs and mice.

In general, animal studies on L. reuteri are done using the species-specific strain of the bacterium.

Protection against pathogens

Limosilactobacillus reuteri confers a high level of resistance to the pathogen Salmonella typhimurium, halving mortality rates in mice. The same is true for chickens and turkeys; L. reuteri greatly moderates the morbidity and mortality caused by this dangerous food-borne pathogen.

Limosilactobacillus reuteri is effective in stopping harmful strains of E. coli from affecting their hosts. A study performed in chickens showed L. reuteri was as potent as the antibiotic gentamicin in preventing E. coli-related deaths.

The protozoic parasite Cryptosporidium parvum causes severe watery diarrhea, which can become life-threatening in immunocompromised (as in individuals infected with HIV) patients. L. reuteri is known to lessen the symptoms of C. parvum infection in mice and pigs.

Some protective effect against the yeast Candida albicans has been found in mice, but in this case, L. reuteri did not work as well as other probiotic organisms, such as L. acidophilus and L. casei.

Body weight and growth

In juvenile commercial livestock, such as turkey poults and piglets, body weight and growth rate are good health indicators. Animals raised in the dirty, crowded environments of commercial farms are generally less healthy (and therefore weigh less) than their counterparts born and bred in cleaner spaces. In turkeys, for example, this phenomenon is known as "poult growth depression", or PGD.

Supplementing the diets of these young animals with L. reuteri helps them to largely overcome the stresses imposed by unhealthy environs. Commercial turkeys fed L. reuteri from birth had nearly a 10% higher adult body weight than their peers raised in the same conditions. A similar study on piglets showed L. reuteri is at least as effective as synthetic antibiotics in improving body weight under crowded conditions.

The mechanism by which L. reuteri is able to support healthy growth is not entirely understood. It possibly serves to protect against illness caused by S. typhimurium and other pathogens (see above), which are much more common in crowded commercial farms. However, other studies found that it can help when the growth depression is caused entirely by a lack of dietary protein, and not by contagious disease. This raises the possibility that L. reuteri somehow improves the intestines' ability to absorb and process nutrients.

Chemical and trauma-induced injury

Treating colonic tissue from rats with acetic acid causes an injury similar to the human condition ulcerative colitis. Treating the injured tissue with L. reuteri immediately after removing the acid almost completely reverses any ill effects, leading to the possibility that L. reuteri may be beneficial in the treatment of human colitis patients.

In addition to its role in digestion, the intestinal wall is also vital in preventing harmful bacteria, endotoxins, etc., from "leaking" into the bloodstream. This leaking, known as bacterial "translocation", can lead to lethal conditions such as sepsis. In humans, translocation is more likely to occur following such events as liver injury and ingestion of some poisons. In rodent studies, L. reuteri was found to greatly reduce the amount of bacterial translocation following either the surgical removal of the liver or injection with D-galactosamine, a chemical which causes liver damage.

The anticancer drug methotrexate causes severe enterocolitis in high doses. L. reuteri greatly mitigates the symptoms of methotrexate-induced enterocolitis in rats, one of which is bacterial translocation.

Links to fat in diet of mice, and reversible symptoms of behavioral abnormalities

In mice, the absence of L. reuteri has been causally linked to maternal diet. A gut microbial imbalance, lacking in L. reuteri, was linked to behavioral abnormalities consistent with autism in humans. These symptoms were reversible by supplementing L. reuteri.

References

References

1. Orla-Jensen, S. 1919. The lactic acid Bacteria. Det Kongelige Danske Videnskasbernes Selskab. Naturvidenskabelige mathematiske Afdeling, NS 8.5.2
2. Reuter G.. (1965). "Das vorkommen von laktobazillen in lebensmitteln und ihr verhalten im menschlichen intestinaltrakt". ZBL. Bak. Parasit. Infec. Hyg. I Orig..
3. (1980). "''Lactobacillus reuteri'' sp. nov. a new species of heterofermentative lactobacilli". ZBL. Bakt. Hyg. Abt. Orig..
4. (2020). "A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae". International Journal of Systematic and Evolutionary Microbiology.
5. (1965). "Das vorkommen aerob wachsender grampositiver stabchen des genus Lactobacuillus beijerinck im darminhalt erwachsener menchen". ZBL. Bak. Parasit. Infec. Hyg. I Orig..
6. (1981). "Classification of citratefermenting lactobacilli isolated from lamb stomach, sheep milk, and pecorino romano cheese". ZBL. Bakt. Hyg. Abt. Orig..
7. (March 1993). "Numerical taxonomy of ''Lactobacillus spp.'' associated with healthy and diseased mucosa of the human intestines". Journal of Applied Bacteriology.
8. (1985). "Taxonomy of lactobacilli isolated from the alimentary tract of chickens". Syst Appl Microbiol.
9. (August 1995). "Development of intestinal lactobacilli in normal piglets". Journal of Applied Bacteriology.
10. (April 1992). "Systematics of the ''Lactobacillus'' population on rat intestinal mucosa with special reference to ''Lactobacillus reuteri''". Antonie van Leeuwenhoek.
11. Mitsuoka T. (1992). "The lactic acid bacteria in health and disease". Elsevier Applied Science.
12. (1997). "''Lactobacillus reuteri'': An overview of a new probiotic for humans and animals". Microecol Therap.
13. (2000). "Validation of the Probiotic Concept: ''Lactobacillus reuteri'' Confers Broad-spectrum Protection against Disease in Humans and Animals". Microbial Ecology in Health and Disease.
14. (2019-08-02). "Lifestyles of sourdough lactobacilli - Do they matter for microbial ecology and bread quality?". International Journal of Food Microbiology.
15. (1950). "Acid-catalysed hydration of acrylalde. Kinetics of the reaction and isolation of β-hydroxypropionaldehyde". J Chem Soc.
16. "¹³C and ¹H NMR study of formaldehyde reactions with acetaldehyde and acrolein. Synthesis of 2-(hydroxymethyl)-1,3-propanediol". Pol J Chem.
17. (May 2003). "Purification and structural characterization of 3-hydroxypropionaldehyde and its derivatives". J. Agric. Food Chem..
18. (May 1989). "Chemical characterization of an antimicrobial substance produced by ''Lactobacillus reuteri''". Antimicrob. Agents Chemother..
19. (January 2008). "Glycerol induces reuterin production and decreases Escherichia coli population in an in vitro model of colonic fermentation with immobilized human feces". FEMS Microbiol. Ecol..
20. (June 2008). "Comparative genome analysis of ''Lactobacillus reuteri'' and ''Lactobacillus fermentum'' reveal a genomic island for reuterin and cobalamin production". DNA Res..
21. (1995). "Safety and tolerance of Lactobacillus reuteri in healthy adult male subjects". Microb Ecol Health Dis.
22. (2005). "Occurrence of ''Lactobacillus reuteri'', lactobacilli and bifidobacteria in human breast milk". Pediatr Res.
23. (2005). "Intestinal microbiota in infants supplemented with the probiotic bacterium ''Lactobacillus reuteri''". J Ped Gastroenterol Nutr.
24. (2016). "Diet therapy for inflammatory bowel diseases: The established and the new". World J Gastroenterol.
25. (2006). "Probiotic use in clinical practice: what are the risks?". Am J Clin Nutr.
26. (2015). "Risk and safety of probiotics.". Clin Infect Dis.
27. (2016). "Probiotics in critically ill children". F1000Res.
28. (May 2016). "Systematic review with meta-analysis: Lactobacillus reuteri DSM 17938 for diarrhoeal diseases in children". Aliment Pharmacol Ther.
29. (September 2015). "Meta-analysis: Lactobacillus reuteri strain DSM 17938 (and the original strain ATCC 55730) for treating acute gastroenteritis in children". Benef Microbes.
30. (December 1997). "Bacteriotherapy with ''Lactobacillus reuteri'' in rotavirus gastroenteritis". Pediatr. Infect. Dis. J..
31. (1996). "Feeding of a probiotic for the prevention of community-acquired diarrhea in young Mexican children". Pediatr Res.
32. Romeo MG, Betta P, Oliveri S. (2006) Presented at the 5th Annual meeting of the Italian Society of Perinatal Medicine, Parma, Italy, 15–17 June 2006. Abstract published in J Perinat Med 34(Suppl 1): A9, abstract MSL_24.
33. Guerrero M, Dohnalek M, Newton P, Kuznetsova O, Ruiz-Palacios G, Murphy T, Calva J, Hilty M, Costigan T., 1st World Congress of Pediatric Infectious Diseases, Dec. 1996, abstract no. 610:45-2.
34. (Oct 2010). "Luminal administration ex vivo of a live Lactobacillus species moderates mouse jejunal motility within minutes". FASEB J.
35. (June 9, 2015). "Lactobacillus reuteri DSM 17938 as a Probiotic for Preterm Neonates: A Strain-Specific Systematic Review.". JPEN J Parenter Enteral Nutr.
36. (March 2, 2016). "Probiotics for the Treatment of Infantile Colic: A Systematic Review.". J Pharm Pract.
37. (May 2016). "Infant Colic-What works: A Systematic Review of Interventions for Breast-fed Infants". J Pediatr Gastroenterol Nutr.
38. Elena A Kornienko, Natalia I. Parolova, Sergey V. Ivanov, Dmitry S Polev, Pavel A Zykin, Yulia D. Kontratenko, Mikhail M. Zakharchenco (January 16, 2020) "Gastric microbiota and probiotics opportunities in ''helicobacter pylori'' eradication in children."
39. (2007). "''Lactobacillus reuteri'' (ATCC strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study". Pediatrics.
40. (2010). "''Lactobacillus reuteri'' DSM 17938 in Infantile Colic: A Randomized, Double-Blind, Placebo-Controlled Trial". Pediatrics.
41. Parolova NI, Kornienko EA, Antonov PV Egorov Mikhail Gorbunov EF, Dmitrienko MA (2015) '') "''An innovative approach in the treatment of ''H. pylori'' infection in children."
42. (July 2007). "''Lactobacillus reuteri'' tablets suppress ''Helicobacter pylori'' infection—a double-blind randomised placebo-controlled cross-over clinical study". Kansenshogaku Zasshi.
43. (2005). "''Helicobacter pylori'' eradication with ''Lactobacillus reuteri''. A double blind placebo-controlled study". Dig Liver Dis.
44. (April 2008). "Inhibition of Helicobacter pylori infection in humans by ''Lactobacillus reuteri ATCC 55730'' and effect on eradication therapy: a pilot study". Helicobacter.
45. Buckley M, Lacey S, Doolan A, Goodbody E, Seamans K (2018), "The effect of ''Lactobacillus reuteri'' supplementation in ''Helicobacter pylori'' infection: a placebo-controlled, single-blind study." BMC nutrition.
46. Yang C, Liang L, Pinjing Lv, Liu L, Wang S, Wang Z, Chen Y (2021) "Effects of non-viable ''Lactobacillus reuteri'' combining with 14-days standard triple therapy on ''Helicobacter pylori'' eradication: A randomized double blind placebo-controlled trial.
47. Holz C, Busjahn A, Mehling H, Arya S, Boettner M, Habibi H, Lang C, (2014). "Significant Reduction in ''Helicobacter pylori'' Load in Humans with Non-viable ''Lactobacillus reuteri'' DSM17648: A Pilot Study". Probiotics & Antimicro. Prot
48. Mihai C, Mihai BM, Dranga M, Cardoneanu A, Prelipcean CC (2019) "Lactobacillus reuteri – an alternative in the first-line of helicobacter pylori eradication". Farmacia, Vol. 67, 5
49. (September 2004). "''Lactobacillus reuteri'' in bovine milk fermented decreases the oral carriage of mutans streptococci". Int. J. Food Microbiol..
50. (2006). "Decreased gum bleeding and reduced gingivitis by the probiotic ''Lactobacillus reuteri''". Swed Dent J.
51. (23 February 2022). "Fun facts about bones: More than just scaffolding". Knowable Magazine.
52. (September 2018). "Lactobacillus reuteri reduces bone loss in older women with low bone mineral density: a randomized, placebo-controlled, double-blind, clinical trial". Journal of Internal Medicine.
53. (November 2019). "Probiotic treatment using a mix of three Lactobacillus strains for lumbar spine bone loss in postmenopausal women: a randomised, double-blind, placebo-controlled, multicentre trial". The Lancet Rheumatology.
54. (2020). "Gut Microbiome and Osteoporosis". Aging and Disease.
55. (19 February 2021). "Healthy Gut, Healthy Bones: Targeting the Gut Microbiome to Promote Bone Health". Frontiers in Endocrinology.
56. (January 2005). "Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents". Pediatrics.
57. (2005). "Increasing work-place healthiness with the probiotic ''Lactobacillus reuteri'': a randomised, double-blind placebo-controlled study". Environ Health.
58. Carbajal N, Sriburi A, Carter P, Dobrogosz W, Casas, I. Probiotic administrations of Lactobacillus reuteri protect mice from Salmonella typhimurium infection. Proceedings of the 36th Annual Meeting of the Association for Gnotobiotics. 1998 Jun 14–16; Bethesda (MD): Association for Gnotobiotics; 1998.
59. Casas IA, Edens FW, [[Dobrogosz WJ]]. Lactobacillus reuteri: an effective probiotic for poultry and other animals. Lactic acid bacteria, 2nd ed. New York: Marcel Dekker, 1998: 475–518.
60. (January 1997). "Principles of ex ovo competitive exclusion and in ovo administration of ''Lactobacillus reuteri''". Poult. Sci..
61. (January 1997). "Effect of ''Lactobacillus reuteri'' on intestinal resistance to Cryptosporidium parvum infection in a murine model of acquired immunodeficiency syndrome". J. Infect. Dis..
62. (October 1997). "Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice". Infect. Immun..
63. Barnes JH. (1993). "Evaluating poult growth and productivity during brooding". Turkeys.
64. (1998). "Probiotic treatment with ''Lactobacillus reuteri'' protects commercial turkeys from avian growth depression". Biosci Microflora.
65. Blanchard P, Gill P, Schulze H. Efficacy of ''Lactobacillus reuteri'' 1063-IA in pre- and post-weaning pigs. Hertfordshire SG5 4JG (UK): MLC Stotfold Pig Development Unit; 1998. Study Reference No. FF9801.
66. (1998). "Avian growth depression in chickens induced by environmental, microbiological, or nutritional stress is moderated by probiotic administrations of ''Lactobacillus reuteri''". Biosci Microflora.
67. (February 1993). "The effect of exogenous administration of ''Lactobacillus reuteri R2LC'' and oat fiber on acetic acid-induced colitis in the rat". Scand. J. Gastroenterol..
68. (February 1995). "The role of oral administration of oatmeal fermented by ''Lactobacillus reuteri R2LC'' on bacterial translocation after acute liver failure induced by subtotal liver resection in the rat". Scand. J. Gastroenterol..
69. (March 1997). "Effect of ''Lactobacillus'' supplementation with and without arginine on liver damage and bacterial translocation in an acute liver injury model in the rat". Hepatology.
70. (August 1996). "The effects of ''Lactobacillus'' strains and oat fiber on methotrexate-induced enterocolitis in rats". Gastroenterology.
71. (2016). "Microbial Reconstitution Reverses Maternal Diet-Induced Social and Synaptic Deficits in Offspring". Cell.